April 27, 2012 |
The Food and Drug Administration warned Friday that doctors should not prescribe and patients should not use the hepatitis C drug Victrelis (boceprevir) and the anti-HIV drug ritonavir at the same time because such use reduces the effectiveness of both drugs. Patients already using the two drugs simultaneously should not stop taking them without consulting their doctor, however, the agency cautioned. Ritonavir, a protease inhibitor, is commonly used to boost the effectiveness of other protease inhibitors and is found in Reyataz (atazanavir/ritonavir)
February 21, 2012 |
Hepatitis C mortality rates surpassed HIV mortality rates in the United States in 2007, researchers said Monday. In a study in the journal Annals of Internal Medicine ( abstract here ), U.S. Centers for Disease Control researchers analyzed causes of death on more than 21.8 million U.S. death certificates filed between 1999 and 2007. Rates of death related to hepatitis C, a viral infection that causes chronic liver disease, rose at an average rate of .18 deaths per 100,000 persons per year.
January 18, 2012 |
A major advance in treating hepatitis C appears to be on the horizon. Researchers reported Wednesday that combining two antiviral medications was effective in stopping the infection in some patients who were not helped by the traditional treatment. Progress in fighting hepatitis C infection is of high importance because millions of Americans have the virus. However, the standard treatment with the medication interferon, while effective in many people, is linked to severe side effects.
November 21, 2011
Gilead Sciences Inc struck a deal to buy biotechnology company Pharmasset Inc for about $11 billion in a huge bet to diversify its portfolio with new hepatitis C treatments. Gilead, the world's largest maker of HIV drugs, will pay $137 per share for each Pharmasset share, an 89% premium to Pharmasset's Friday closing price. Pharmasset has been one of the hottest biotech stocks in the last year based on the potential of its experimental hepatitis C medicines to create a treatment regimen for the liver disease without commercially manufactured interferons.
CALIFORNIA | LOCAL
October 11, 2011 |
Gov. Jerry Brown on Monday signed two bills that will expand access to sterile syringes for drug users in an effort to combat the spread of hepatitis C and HIV. The first bill, written by Sen. Leland Yee (D-San Francisco), allows people to buy syringes at pharmacies without a prescription. California was one of the few states where this was illegal, other than in a few pilot program areas. The second bill, introduced by Assemblywoman Nancy Skinner (D-Berkeley), allows the state to authorize needle exchange programs in areas deemed high risk for the spread of disease.
July 26, 2011
For a generally progressive state, California falls surprisingly behind on certain issues. One of these is allowing the purchase of syringes without a prescription. Syringes are already an over-the-counter medical supply in 47 states. It's long past time for the same to be true in California. A pilot program signed into law in 2004 by Gov. Arnold Schwarzenegger allowed sales of syringes by pharmacies in counties that elected to join. Los Angeles was one of those. Yes, most of the sales were to addicts, who used the syringes to further their use of illegal drugs.
July 21, 2011 |
The hepatitis C virus, normally thought to be transmitted exclusively through blood - such as by sharing of needles among intravenous drug abusers - can also be transmitted through sexual activity, principally through anal sex among gay men, a growing body of evidence suggests. The most recent evidence was reported Thursday by New York City researchers who documented an outbreak of the virus, commonly known as HCV, among gay men. Hepatitis C, which can cause severe liver disease and even death if left untreated, affects an estimated 3.2 million Americans.
May 23, 2011 |
The Food and Drug Administration on Monday approved telaprevir for the treatment of hepatitis C, the second drug for the disease approved in two weeks. On May 13, the agency approved boceprevir, sold under the brand name Victrelis. The two drugs are the first new treatments for hepatitis C in 20 years. Both are members of a new class of drugs called protease inhibitors that block replication of an enzyme that is crucial to the replication of the virus. Like boceprevir, telaprevir, sold under the brand name Incivek by Vertex Pharmaceuticals Inc. of Cambridge, Mass., is meant to be used only in conjunction with the standard therapy of peginterferon-alpha and ribavirin.
May 13, 2011 |
The Food and Drug Administration on Friday approved marketing of the Merck drug boceprevir, the first new drug for hepatitis C in 20 years. The agency is still considering approval of a similar drug, telaprevir, and is expected to approve it soon as well. Both drugs are members of a new class of hepatitis drugs called protease inhibitors, which block a key enzyme required by the virus to replicate. They are expected to convert hepatitis C from a debilitating disease into a manageable condition for the majority of people infected with the virus.
May 12, 2011 |
Not only can bedbugs harbor MRSA, they could potentially, just maybe, spread the drug-resistant bacteria, researchers – and resulting headlines — are speculating. The thought is a scary one, but not much different than what we already knew about the threat from these generally nocturnal parasites . It’s certainly plausible that a blood-sucking bug can spread blood-transmitted diseases, but scientists haven’t found much evidence they do so. Here’s the low-down on what’s known on bedbugs and disease.